We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

New M&A Transaction Structures: Perspectives of the Biotech Industry

30 September 2007

Pharm. Ind. 69, Nr. 9, 1024-1026 (2007)
The tense financing situation for biotech companies in Germany has lead to an increased interest in innovative transaction models that offer chances for growth even in a difficult environment. For participating German companies, two transaction structures have proven to be most attractive. This article introduces these structures using concrete projects: the acquisition of an insolvent life science business and the "reverse merger" model.
Loading data